- Todos > Medicine Access and Rational Use > Rational Use
- Todos > Medicine Access and Rational Use > Selection
- Todos > Medicine Access and Rational Use > Supply Management
- Todos > Quality and Safety: Medicines > Quality Assurance
- Todos > Quality and Safety: Medicines > Regulatory Support
- Todos > Quality and Safety: Medicines > Safety and Efficacy
- Todos > WHO Prequalification of Medical Products > WHO-UNICEF-UN Project
- Todos > Diagnostics and Laboratory Technology > Evaluation of Diagnostics
- Todos > Diagnostics and Laboratory Technology > Quality Assurance
- Palabras clave > acceptability - using a specific investigational medicinal product, IVDs, vaccines
- Palabras clave > clinical trials novel product - public health emergency
- Palabras clave > emergency situations
- Palabras clave > Emergency Use Assessment and Listing Procedure (EUAL)
- Palabras clave > Good Manufacturing Practices (GMP)
- Palabras clave > good quality in vitro diagnostics (IVDs)
- Palabras clave > post-emergency-use-listing safety monitoring - medicines, IVDs, vaccines granted EUAL
- Palabras clave > Public Health Emergency of International Concern (PHEIC)
- Palabras clave > in vitro Diagnostic (IVD)
- Palabras clave > WHO EUAL List - Candidate Medicinal Products, IVDs, Vaccines
Emergency Use Assessment and Listing Procedure (EUAL) for Candidate in Vitro Diagnostics (IVDs) for Use in the Context of a Public Health Emergency
(2015; 11 pages)
(2015; 11 pages)
Resumen

The 2014 Ebola outbreak is the largest Ebola epidemic in history, which affected multiple countries in West Africa. This epidemic has demonstrated the need for a WHO emergency use assessment and listing procedure (EUAL) for candidate in vitro diagnostics (IVDs) for use in the context of a public health emergency. The purpose of this extraordinary procedure is to provide guidance to interested UN procurement agencies and national regulatory authorities (NRAs) of relevant WHO Member States. The present document describes the EUAL for candidate IVDs and is primarily aimed at manufacturers of these IVDs in the context of use during a public health emergency. Participation in the procedure is voluntary.